Grimm Alexander, Décard Bernhard F, Schramm Axel, Pröbstel Anne-Katrin, Rasenack Maria, Axer Hubertus, Fuhr Peter
Department of Neurology, Basel University Hospital, Basel, Switzerland; Department of Neurology, University of Tuebingen, Tuebingen, Germany.
Department of Neurology, Basel University Hospital, Basel, Switzerland.
Clin Neurophysiol. 2016 Feb;127(2):1657-1663. doi: 10.1016/j.clinph.2015.06.032. Epub 2015 Jul 21.
To investigate cross-sectional areas (CSAs) of several peripheral nerves including the vagus nerve and the diameter of spinal nerves as measured by nerve ultrasound (NUS) and nerve conduction studies (NCS) in Guillain-Barré syndrome (GBS) patients over at least six months compared to healthy controls.
NUS and/or NCS of several nerves, the vagus nerve, and the 5th/6th cervical spinal nerves were performed in patients with GBS at days 2-3 after symptom onset, at days 10-14 after immunoglobulin therapy and after six months compared to healthy controls.
27 GBS-patients and 31 controls were included. Using NUS significant enlargement was found in all measured nerves (P<0.001), except the sural nerve (P=0.086) compared to the controls at onset. The vagus (median 3.0 mm(2) vs. 2.0 mm(2), P<0.0001) and the cervical spinal nerves were significantly enlarged (median 3.5/4.0 mm vs. 2.6/3.2 mm, p<0.0001), the vagus most obviously in patients with autonomic dysregulation (AD, 4.0 mm(2)). Six months later, NCS showed persisting pathology in CMAP-amplitudes with amelioration of F-wave pathology. NUS showed restitution in the spinal nerves (median 2.6/3.2 mm) and the vagus (median 2.0 mm(2)) in all patients excluding the vagus in those with persistent AD (median 4.0 mm(2)). The peripheral nerves did not change significantly (P>0.05).
Ultrasonographic detection of cervical spinal nerve enlargement supports the diagnosis of GBS in the early phase. Its regression may be a good parameter for the clinical restitution over time. Vagus enlargement may be a risk marker for development of AD.
Ultrasound is a reliable diagnostic follow-up tool in early GBS.
通过神经超声(NUS)和神经传导研究(NCS)测量格林-巴利综合征(GBS)患者至少六个月内包括迷走神经在内的多条周围神经的横截面积(CSA)以及脊神经直径,并与健康对照进行比较。
在症状出现后第2 - 3天、免疫球蛋白治疗后第10 - 14天以及六个月后,对GBS患者的多条神经、迷走神经和第5/6颈脊神经进行NUS和/或NCS检查,并与健康对照进行比较。
纳入27例GBS患者和31例对照。与发病时的对照相比,使用NUS发现除腓肠神经外(P = 0.086),所有测量神经均有显著增粗(P < 0.001)。迷走神经(中位数3.0平方毫米对2.0平方毫米,P < 0.0001)和颈脊神经显著增粗(中位数3.5/4.0毫米对2.6/3.2毫米,p < 0.0001),迷走神经在自主神经功能失调(AD)患者中增粗最明显(4.0平方毫米)。六个月后,NCS显示复合肌肉动作电位(CMAP)波幅持续存在病变,F波病变有所改善。NUS显示所有患者的脊神经(中位数2.6/3.2毫米)和迷走神经(中位数2.0平方毫米)恢复,持续性AD患者的迷走神经除外(中位数4.0平方毫米)。周围神经无显著变化(P > 0.05)。
超声检测到颈脊神经增粗支持GBS早期诊断。其恢复情况可能是随时间临床恢复的良好指标。迷走神经增粗可能是AD发生的风险标志物。
超声是GBS早期可靠的诊断随访工具。